# Fresenius Medical Care AG > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Fresenius Medical Care AG). ## Overview Fresenius Medical Care AG is a renal care company built around dialysis treatment and related products for people with chronic kidney disease and end-stage renal disease. Its business combines a global network of dialysis clinics with the manufacture and supply of dialysis machines, dialyzers, and related renal care products, and it operates through both healthcare delivery and product segments. ## Products & services • Dialysis treatments in clinic-based care networks • Dialysis machines and therapy systems • Dialyzers and other disposable dialysis products • Renal pharmaceuticals and related supply arrangements • Value-based kidney care and care coordination platforms - **Care Delivery** (55%) — In-clinic dialysis services and extracorporeal therapies for kidney disease patients. - **Care Enablement** (35%) — Manufacture and distribution of dialysis products, equipment, and related services. - **Value-Based Care** (10%) — Kidney care contracting, clinical management, and tech-enabled care coordination. - Dialysis treatments in clinic-based care networks - Dialysis machines and therapy systems - Dialyzers and other disposable dialysis products - Renal pharmaceuticals and related supply arrangements - Value-based kidney care and care coordination platforms ## Customers The company serves patients with chronic kidney disease and end-stage renal disease through dialysis clinics and related care services. It also sells dialysis equipment and consumables to healthcare providers, clinics, and care systems that deliver renal therapy. In addition, its value-based kidney care activities address payors and provider networks that manage total cost and outcomes for kidney populations. - **Dialysis patients** (primary) — Patients with CKD or ESRD receiving recurring dialysis treatments in FMC clinics. - **Healthcare providers** (primary) — Hospitals, clinics, and renal care providers buying dialysis machines and consumables. - **Payors and managed care organizations** (secondary) — Private insurers and government programs contracting for kidney care management and shared-savings arrangements. - **Nephrology networks** (secondary) — Physician groups and care networks using platforms and services for coordinated kidney care. - Patients needing chronic dialysis treatment - Hospitals and dialysis providers buying equipment and disposables - Clinics and health systems outsourcing renal care capacity - Private payors and government programs in value-based kidney care - Nephrology networks and care coordinators managing patient populations ## Geography Fresenius Medical Care operates globally, with a large clinic footprint and product sales across North America, Europe, and other international markets. Its operating model depends on local reimbursement systems, healthcare regulations, and clinical networks, so geography directly affects patient mix, pricing, and service delivery. The reported business description emphasizes worldwide operations rather than a single domestic market. - Global dialysis clinic network spanning multiple regions - North America is strategically important for clinic and product demand - Europe remains a core market for renal care services and products - International exposure adds reimbursement and regulatory complexity - Local healthcare systems shape treatment volumes and pricing ## Strategy The company is focused on integrating dialysis care delivery with dialysis products and value-based kidney care models. Its strategic direction centers on using its clinical network, proprietary informatics, and patient engagement tools to improve kidney outcomes while supporting recurring demand for therapies and consumables. Capital allocation discipline and shareholder returns are presented as part of its broader execution framework. - **Strengthen integrated renal care model** (medium-term) — Combining clinics, products, and care management increases patient retention and supports recurring demand. - **Scale value-based kidney care** (medium-term) — Shared-savings and risk-based contracts can deepen payor relationships and broaden addressable care models. - **Improve capital efficiency** (short-term) — Capital discipline supports shareholder returns while preserving flexibility for operational investment. - Integrate dialysis clinics with product supply and care coordination - Expand value-based kidney care and shared-savings arrangements - Use informatics and patient engagement tools in care management - Support recurring demand through clinical and product breadth - Maintain disciplined capital allocation and shareholder returns ## Risks The business depends on stable reimbursement, clinical utilization, and patient access to dialysis, so changes in payor policy or care patterns can affect volumes and economics. It also faces operational exposure from healthcare regulation, supply chain execution, foreign exchange, and the complexity of managing clinics and product manufacturing across many jurisdictions. In value-based care, shared-savings or full-risk arrangements create additional variability because outcomes, utilization, and medical costs affect results directly. - **Reimbursement and payor policy changes** [high] — Dialysis and kidney care economics depend heavily on public and private reimbursement rates and coverage rules. - **Healthcare operating complexity** [high] — Running thousands of clinics requires staffing, regulatory compliance, and consistent treatment quality. - **Foreign exchange volatility** [medium] — Global operations create translation and transaction exposure across currencies. - **Value-based care downside risk** [medium] — Shared-loss or full-risk arrangements can reduce earnings if patient costs exceed expectations. - Reimbursement pressure can affect dialysis volumes and pricing - Clinical labor and clinic operations are complex and cost-sensitive - Supply chain and manufacturing disruptions can affect product availability - FX volatility matters because the business is globally diversified - Value-based care contracts create outcome and medical-cost risk ## Accounting Revenue recognition is complex because the company combines clinic services, product sales, shared-savings arrangements, and insurance-like risk contracts. The reports also show meaningful use of IFRS 15 and IFRS 17 for value-based and full-risk arrangements, while lease accounting and foreign exchange effects matter because of the large clinic network and international footprint. Related-party supply and equity-method arrangements, as well as share-based compensation and fair-value measurements, can also affect comparability across periods. - **IFRS 15 and IFRS 17 in value-based care** — Shared-savings revenue and premium/claim accounting - **Lease accounting** — Depreciation, interest expense, and operating leverage - **Foreign exchange effects** — Other operating income and period-to-period comparability - **Related-party transactions** — Revenue, cost of sales, and disclosure complexity - Value-based care revenue may be recognized under IFRS 15 or IFRS 17 - Shared-savings and full-risk contracts affect revenue timing and volatility - Clinic leases make IFRS 16 lease accounting relevant - Foreign exchange gains and losses can move other operating income - Related-party and equity-method transactions affect comparability --- *Last updated: 2026-09-28T12:03:40.869396+00:00*